Literature DB >> 9690377

p53 and follow-up of colorectal adenocarcinomas.

A Polge1, J F Bourgaux, E Bancel, C Pignodel, J C Boyer, S Poirey, B M de Bornier, J L Balmes, J P Bali.   

Abstract

Circulating p53 antibodies (ELISA method), p53 genetic alterations (SSCP), and protein overexpression (immunohistochemistry) were studied in 41 patients with colorectal adenocarcinomas and 10 control patients. Carcinoembryonic antigen (CEA) and carbohydrate antigen 19.9 (CA 19-9) were evaluated in parallel. Ten patients with p53 antibodies and p53 overexpression were selected. Tumor DNA extracts from these 10 patients were analyzed by SSCP. Of all 41 patients, 10 (24%) showed significant levels of p53 antibodies, and p53 accumulation was detected in 20 (48%) patients. In six patients, p53 antibody concentrations decreased rapidly after surgery; in two patients, these levels returned to normal values. Of the 10 selected tumors, eight revealed TP53 gene mutations. Only two patients with high values of both CEA and CA 19-9 developed p53 antibodies. In conclusion, beside classical tumor markers, circulating p53 antibodies may be considered as additional markers for the management of patients with colorectal adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690377     DOI: 10.1023/a:1018890126260

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.

Authors:  P Hammel; B Boissier; M T Chaumette; P Piedbois; N Rotman; J C Kouyoumdjian; R Lubin; J C Delchier; T Soussi
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

3.  Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors.

Authors:  Y Shibata; H Kotanagi; H Andoh; K Koyama; H Itoh; S Kudo
Journal:  Dis Colon Rectum       Date:  1996-11       Impact factor: 4.585

4.  Detection of serum anti p53 antibodies and their correlation with p53 mutations in myelodysplastic syndromes and acute myeloid leukemia.

Authors:  C Preudhomme; R Lubin; P Lepelley; M Vanrumbeke; P Fenaux
Journal:  Leukemia       Date:  1994-09       Impact factor: 11.528

5.  Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface.

Authors:  R Lubin; B Schlichtholz; D Bengoufa; G Zalcman; J Trédaniel; A Hirsch; C Caron de Fromentel; C Preudhomme; P Fenaux; G Fournier; P Mangin; P Laurent-Puig; G Pelletier; M Schlumberger; F Desgrandchamps; A Le Duc; J P Peyrat; N Janin; B Bressac; T Soussi
Journal:  Cancer Res       Date:  1993-12-15       Impact factor: 12.701

Review 6.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

7.  p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue.

Authors:  C P Wild; M Ridanpää; S Anttila; R Lubin; T Soussi; K Husgafvel-Pursiainen; H Vainio
Journal:  Int J Cancer       Date:  1995-06-22       Impact factor: 7.396

8.  p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers.

Authors:  A Hartmann; H Blaszyk; R M McGovern; J J Schroeder; J Cunningham; E M De Vries; J S Kovach; S S Sommer
Journal:  Oncogene       Date:  1995-02-16       Impact factor: 9.867

Review 9.  The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis.

Authors:  A J Levine; M E Perry; A Chang; A Silver; D Dittmer; M Wu; D Welsh
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

10.  The relationship between serum p53 autoantibodies and characteristics of human breast cancer.

Authors:  B Mudenda; J A Green; B Green; J R Jenkins; L Robertson; M Tarunina; S J Leinster
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

View more
  5 in total

1.  Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer.

Authors:  Luis C Fernandes; Su B Kim; Sarhan S Saad; Delcio Matos
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

Review 2.  Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer.

Authors:  Aravind Suppiah; John Greenman
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

3.  Potential diagnostic value of serum p53 antibody for detecting esophageal cancer: a meta-analysis.

Authors:  Jun Zhang; Zhiwei Xv; Xuefeng Wu; Ke Li
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

4.  Detection of p73 antibodies in patients with various types of cancer: immunological characterization.

Authors:  O Tominaga; K Unsal; G Zalcman; T Soussi
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

5.  Serum anti-p53 antibody as a tumour marker for colorectal cancer screening.

Authors:  Masaya Iwamuro; Yoshinari Kawai; Tomoko Matsumoto; Masashi Uda; Hiroyuki Okada
Journal:  Ecancermedicalscience       Date:  2015-07-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.